Howell A, Barnes D M, Harland R N, Redford J, Bramwell V H, Wilkinson M J, Swindell R, Crowther D, Sellwood R A
Lancet. 1984 Mar 17;1(8377):588-91. doi: 10.1016/s0140-6736(84)90995-4.
Oestrogen receptors were measured in the primary breast tumours of 508 patients and progesterone receptors in those of 486 patients. Survival from mastectomy was significantly longer in patients with receptor-positive tumours. There was no significant difference between patients with receptor-positive and receptor-negative tumours in the relapse-free interval, but survival from first relapse was longer in patients with receptor-positive tumours. Axillary node status and tumour size indicated the probability of relapse but did not influence the length of survival after relapse. Response to tamoxifen or ovarian ablation was known in 65 of the 137 patients who relapsed. Survival from first relapse was significantly longer in patients who both responded to hormone therapy and had receptor-positive tumours. Patients who did not respond to hormone therapy and had receptor-positive tumours had the same survival characteristics as those with receptor-negative tumours who did not respond.
在508例患者的原发性乳腺肿瘤中检测了雌激素受体,在486例患者的肿瘤中检测了孕激素受体。受体阳性肿瘤患者乳房切除术后的生存期明显更长。受体阳性和受体阴性肿瘤患者的无复发生存期没有显著差异,但受体阳性肿瘤患者首次复发后的生存期更长。腋窝淋巴结状态和肿瘤大小提示复发的可能性,但不影响复发后的生存时间。137例复发患者中有65例已知对他莫昔芬或卵巢去势的反应。对激素治疗有反应且肿瘤受体阳性的患者首次复发后的生存期明显更长。对激素治疗无反应但肿瘤受体阳性的患者与对激素治疗无反应的受体阴性肿瘤患者具有相同的生存特征。